---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110883"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:28:16.034644+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx Q3 net loss $50.5M; enters ophthalmology collaboration with Lilly for $75M upfront

## Summary
- Collaboration with Lilly: upfront $75M, eligible for >$400M milestones and tiered royalties on ocular programs.
- Cash $14.8M at Sept 30; with Lilly $75M and Hologen $150M expected, runway into H2 2027 covers $75M debt due Aug 2026.
- Net loss $50.5M ($0.62/share) vs $39.3M ($0.55) YoY; service revenue fell to $0.4M from $10.9M as J&J PPQ substantially completed.
- AAV-hAQP1 Phase 2 enrollment target end of 2025; positive data could support BLA filing early 2027.
- AAV-GAD Phase 3 for Parkinson's expected to initiate in coming months; RMAT designation granted.

## SEC filing metadata
- accession: 0001104659-25-110883
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000110465925110883/0001104659-25-110883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000110465925110883/mgtx-20251113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110883
- JSON: https://secwatch.observer/filing/0001104659-25-110883.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110883.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.